Show simple item record

dc.contributor.authorvan de Weijer, LL
dc.contributor.authorErcolano, E
dc.contributor.authorZhang, T
dc.contributor.authorShah, M
dc.contributor.authorBanton, MC
dc.contributor.authorNa, J
dc.contributor.authorAdams, CL
dc.contributor.authorHilton, D
dc.contributor.authorKurian, KM
dc.contributor.authorHanemann, CO
dc.date.accessioned2024-01-19T11:44:54Z
dc.date.available2024-01-19T11:44:54Z
dc.date.issued2023-12-15
dc.identifier.issn2051-5960
dc.identifier.issn2051-5960
dc.identifier.other198
dc.identifier.urihttps://pearl.plymouth.ac.uk/handle/10026.1/21916
dc.description.abstract

Meningiomas are the most common intracranial brain tumours. These tumours are heterogeneous and encompass a wide spectrum of clinical aggressivity. Treatment options are limited to surgery and radiotherapy and have a risk of post-operative morbidities and radiation neurotoxicity, reflecting the need for new therapies. Three-dimensional (3D) patient-derived cell culture models have been shown to closely recapitulate in vivo tumour biology, including microenvironmental interactions and have emerged as a robust tool for drug development. Here, we established a novel easy-to-use 3D patient-derived meningioma spheroid model using a scaffold-free approach. Patient-derived meningioma spheroids were characterised and compared to patient tissues and traditional monolayer cultures by histology, genomics, and transcriptomics studies. Patient-derived meningioma spheroids closely recapitulated morphological and molecular features of matched patient tissues, including patient histology, genomic alterations, and components of the immune microenvironment, such as a CD68 + and CD163 + positive macrophage cell population. Comprehensive transcriptomic profiling revealed an increase in epithelial-to-mesenchymal transition (EMT) in meningioma spheroids compared to traditional monolayer cultures, confirming this model as a tool to elucidate EMT in meningioma. Therefore, as proof of concept study, we developed a treatment strategy to target EMT in meningioma. We found that combination therapy using the MER tyrosine kinase (MERTK) inhibitor UNC2025 and the histone deacetylase (HDAC) inhibitor Trichostatin A (TSA) effectively decreased meningioma spheroid viability and proliferation. Furthermore, we demonstrated this combination therapy significantly increased the expression of the epithelial marker E-cadherin and had a repressive effect on WHO grade 2-derived spheroid invasion, which is suggestive of a partial reversal of EMT in meningioma spheroids.

dc.format.extent198-
dc.format.mediumElectronic
dc.languageen
dc.publisherSpringer Science and Business Media LLC
dc.subjectMeningioma
dc.subjectSpheroids
dc.subjectEMT
dc.subjectMERTK
dc.subjectHDAC
dc.subjectCombination therapy
dc.titleA novel patient-derived meningioma spheroid model as a tool to study and treat epithelial-to-mesenchymal transition (EMT) in meningiomas
dc.typejournal-article
dc.typeArticle
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/38102708
plymouth.issue1
plymouth.volume11
plymouth.publisher-urlhttp://dx.doi.org/10.1186/s40478-023-01677-9
plymouth.publication-statusPublished online
plymouth.journalActa Neuropathologica Communications
dc.identifier.doi10.1186/s40478-023-01677-9
plymouth.organisational-group|Plymouth
plymouth.organisational-group|Plymouth|Research Groups
plymouth.organisational-group|Plymouth|Faculty of Health
plymouth.organisational-group|Plymouth|Research Groups|Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group|Plymouth|Research Groups|Institute of Translational and Stratified Medicine (ITSMED)|CBR
plymouth.organisational-group|Plymouth|REF 2021 Researchers by UoA
plymouth.organisational-group|Plymouth|Users by role
plymouth.organisational-group|Plymouth|Users by role|Academics
plymouth.organisational-group|Plymouth|REF 2021 Researchers by UoA|UoA01 Clinical Medicine
plymouth.organisational-group|Plymouth|Faculty of Health|Peninsula Medical School
plymouth.organisational-group|Plymouth|Users by role|Researchers in ResearchFish submission
plymouth.organisational-group|Plymouth|REF 2028 Researchers by UoA
plymouth.organisational-group|Plymouth|REF 2028 Researchers by UoA|UoA01 Clinical Medicine
dc.publisher.placeEngland
dcterms.dateAccepted2023-10-23
dc.date.updated2024-01-19T11:44:53Z
dc.rights.embargodate2024-1-27
dc.identifier.eissn2051-5960
rioxxterms.versionofrecord10.1186/s40478-023-01677-9


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV